Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29888262 | 1.00 | LMNA (0.42) | LMNAGAASLC1A5MAPTMAPK1 | |
| SCHEMBL5491257 | 1.00 | LMNA (0.42) | LMNAGAASLC1A5MAPTMAPK1 | |
| SCHEMBL1822157 | 1.00 | LMNA (0.42) | LMNAGAASLC1A5MAPTMAPK1 | |
| SCHEMBL29972014 | 1.00 | LMNA (0.42) | LMNAGAASLC1A5MAPTMAPK1 | |
| SCHEMBL14191690 | 0.83 | GAA (0.44) | LMNAGAAMAPTMAPK1L3MBTL1 | |
| SCHEMBL4014542 | 0.83 | GAA (0.44) | LMNAGAAMAPTMAPK1L3MBTL1 | |
| SCHEMBL4014545 | 0.83 | GAA (0.44) | LMNAGAAMAPTMAPK1L3MBTL1 | |
| SCHEMBL14191688 | 0.82 | CYP3A4 (0.49) | LMNAGAAMAPTMAPK1ALDH1A1 | |
| SCHEMBL12693914 | 0.81 | GAA (0.45) | LMNAGAAMAPTMAPK1L3MBTL1 | |
| SCHEMBL1192238 | 0.81 | ALDH1A1 (0.44) | LMNAGAAMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828305-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2020-11-10 | — | — | US | disclosed |
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-20190091226-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2019-03-28 | — | — | US | disclosed |
| EP-3424928-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2019-01-09 | — | — | EP | disclosed |
| EP-1836174-B1 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-8003787-B2 | Sulphoximine-substituted quinoline and quinazoline derivatives as kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-23 | — | — | US | disclosed |
| EP-1981876-B1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LTD (GB) | 2011-05-04 | — | — | EP | disclosed |
| US-20100158863-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| EP-2152672-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINAZOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-02-17 | — | — | EP | disclosed |
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER HEALTHCARE LLC (DE) | 2009-09-10 | — | — | US | disclosed |
| WO-2008141843-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINAZOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-27 | — | — | WO | disclosed |
| EP-1981876-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | Arrow Therapeutics Limited (GB) | 2008-10-22 | — | — | EP | disclosed |
| EP-1836174-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2007080401-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2007-07-19 | — | — | WO | disclosed |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | AMGEN INC. | 2007-03-08 | — | — | US | disclosed |
| WO-2006039718-A2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158863-A1 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | SLC28A1, TPMT, ACE | LMNA 4439/4885GAA 348/4885SLC1A5 147/4885 |
| US-20190091226-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND USE | ERBB2, EGFR, ERBB4 | LMNA 2686/4885GAA 1911/4885SLC1A5 1528/4885 |
| US-20090226377-A1 | NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | MAP4K2, MAP3K20, MAP3K2 | LMNA 3935/4885GAA 1039/4885SLC1A5 1156/4885 |
| US-20070054916-A1 | Aryl nitrogen-containing bicyclic compounds and methods of use | MAP3K1, MAP3K5, MAP3K2 | LMNA 1675/4885GAA 3670/4885SLC1A5 1360/4885 |
| US-10828305-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use | ERBB2, EGFR, ERBB4 | LMNA 2686/4885GAA 1911/4885SLC1A5 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.